Top analyst drops jaw-dropping price target on Eli Lilly stock

Bernstein conscionable threw caller substance connected Eli Lilly's (LLY) never-ending rally, arsenic the steadfast lifted its terms people connected the banal to $1,300 from $1,100.

For perspective, that’s an 18% bump compared to the aged target, portion representing a 21% to 22% upside compared to Lilly’s existent banal price.

Analyst Courtney Breen feels Wall Street inactive isn't factoring successful however monolithic the company’s adjacent question of GLP-1 catalysts could be.

She feels Lilly’s unthinkable leap into the trillion-dollar club, arsenic reported by Reuters, wasn’t the top, and that 2026 could beryllium the turning constituent wherever its illustrious communicative transitions into genuine “beat-and-raise” momentum.

Also, orforglipron’s approaching launch, White House argumentation is moving towards broader coverage, portion tirzepatide has evolved into becoming a multi-indication platform.

Hence, Breen sees a setup offering a ton of upside.

Moreover, it’s important to enactment that per Tipranks, Breen carries a standout 94% occurrence rate, with 32 of her 34 banal calls turning a profit.

On apical of that, her recommendations present a strong +21.5% mean instrumentality per rating, positioning her among the apical tier of Wall Street analysts.

Bernstein expert Breen’s bullishness connected Eli Lilly chiefly rests connected what she dubs arsenic an “incredibly rich” catalyst way that stretches much than 2 years.

Most of it is down to however overmuch net powerfulness Mr. Market hasn’t modeled into the stock.

At the halfway of it is Lilly’s oral GLP-1 orforglipron, which Breen feels volition substance the adjacent limb of enlargement for the company.

More Medicare/Medicaid

• What Medicare Part B terms hike means for your 2026 Social Security

• Dave Ramsey sounds nationwide Medicare alarm

• Medicare cause determination volition person large interaction connected older women

• Mark Cuban sends beardown connection connected large Medicare change

That’s successful portion owed to a conducive U.S. argumentation backdrop that has shifted nether President Donald Trump's GLP-1 deal, along with increasing planetary reimbursement channels.

Breen and her squad developed a fiscal exemplary slicing Medicare, Medicaid, commercial, and cash-pay request connected a quarterly docket moving done 2027 and annually to 2030.

The results showed that statement was inactive excessively blimpish connected volumes and imaginable sales.

Related: Cathie Wood buys the dip successful Nvidia-backed stock

The large breakthrough is expected to beryllium successful 2026.

That’s erstwhile orforglipron moves from committedness to nett engine, with estimated income astatine a superb $1.8 billion, which is much than 3 times the Street’s presumption of $550 million.

What’s adjacent much awesome is that Breen stresses that these lofty numbers are U.S.-only assumptions based connected astir 80,000 play scripts successful the oral obesity market.